Výsledky vyhledávání - "Frank P. J. Peters"

Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers

Publikováno v: Clinical Genitourinary Cancer, 19(3), 274.e1-274.e16. Elsevier
Clinical Genitourinary Cancer, 19, 274.e1-274.e16
Clinical Genitourinary Cancer, 19(3). Elsevier
Clinical genitourinary cancer, 19(3), 274.e1-274.e16. CIG MEDIA GROUP, LP
Clinical Genitourinary Cancer, 19, 3, pp. 274.e1-274.e16
Verhaart, S L, Abu-Ghanem, Y, Mulder, S F, Oosting, S, Van Der Veldt, A, Osanto, S, Aarts, M J B, Houtsma, D, Peters, F P J, Groenewegen, G, Van Herpen, C M L, Pronk, L M, Tascilar, M, Hamberg, P, Los, M, Vreugdenhil, G, Polee, M, Ten Tije, A J, Haanen, J B A G, Bex, A & van den Eertwegh, A J 2021, ' Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands : An Analysis of Toxicity, Efficacy, and Predictive Markers ', Clinical Genitourinary Cancer, vol. 19, no. 3, pp. 274.e1-274.e16 . https://doi.org/10.1016/j.clgc.2020.10.003

Nivolumab has been approved as second-line treatment for advanced renal cell carcinoma in Europe. We performed a real-world analysis to validate this practice. The study included 264 patients from 24 hospitals in the Netherlands. We found that toxici

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a6df231f2d91880aae6ffa2cce815c
https://pure.eur.nl/en/publications/4db281aa-3dad-4c8e-a105-2442dffa9661

Zobrazit plný text záznamu

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer The ROPETAR Randomized Clinical Trial

Autor: Martijn P. Lolkema, Marco B. Polee, Olaf Loosveld, Paul Hamberg, Geert A. Cirkel, Stefan Sleijfer, Heinz-Josef Klümpen, Johanna E.A. Portielje, Emile E. Voest, Frank P. J. Peters, Vincent van der Noort, Gerard Groenewegen, Maartje Los, Maureen J.B. Aarts, Franchette W P J van den Berkmortel, Laurens V. Beerepoot, John B. A. G. Haanen, Metin Tascilar, M. Wouter Dercksen

Publikováno v: JAMA oncology, 3(4), 501-508. American Medical Association
JAMA Oncology, 3(4), 501-508. American Medical Association

Importance To our knowledge, this is the first randomized clinical trial evaluating an alternating treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma. Objective To test our hypothesis that an 8-week rotati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89bbf142a6a895c6a5a76a5f47e71e11
https://doi.org/10.1001/jamaoncol.2016.5202

Zobrazit plný text záznamu

Neutrophil Recovery in Breast Cancer Patients Receiving Docetaxel-Containing Chemotherapy with and without Granulocyte Colony-Stimulating Factor Prophylaxis

Autor: E.M.G. Jacobs, Frank P. J. Peters, Vivianne C. G. Tjan-Heijnen, Agnes J. van de Wouw, Nelly Peer, Annette W.G. van der Velden, M. Wouter Dercksen, Jacqueline M. Stouthard, Birgit E.P.J. Vriens, Maureen J.B. Aarts, Caroline M.P.W. Mandigers, Jolien Tol, Tineke J. Smilde, Laurence J. C. van Warmerdam, Carin C.D. van der Rijt, Maaike de Boer

Publikováno v: Oncology, 93(5), 323-328. Karger
Oncology (Basel), 93(5), 323-328. Karger
Oncology (Basel: 1948), 93, 323-328
Oncology (Basel: 1948), 93, 5, pp. 323-328

Objective: The primary outcome of the current study is, whether there is a protective effect of prior chemotherapy or of prior granulocyte colony-stimulating factor (G-CSF) on the next cycle blood cell counts. Methods: Hematologic toxicity was evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5e3529e75b98879c2a2e8fa6a9a67d
https://doi.org/10.1159/000479067

Zobrazit plný text záznamu

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Publikováno v: European Urology Focus, 4(5), 694. Elsevier BV
European Urology Focus, 4, 694-701
European urology focus, 4(5), 694-701. Elsevier BV
European Urology Focus, 4(5), 694-701. Elsevier BV
European Urology, 4(5), 694-701. Elsevier
European Urology Focus, 4, 5, pp. 694-701
Westgeest, H M, Uyl-de Groot, C A, van Moorselaar, R J A, de Wit, R, van den Bergh, A C M, Coenen, J L L M, Beerlage, H P, Hendriks, M P, Bos, M M E M, van den Berg, P, van de Wouw, A J, Spermon, R, Boerma, M O, Geenen, M M, Tick, L W, Polee, M B, Bloemendal, H J, Cordia, I, Peters, F P J, de Vos, A I, van den Bosch, J, van den Eertwegh, A J M & Gerritsen, W R 2018, ' Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Focus, vol. 4, no. 5, pp. 694-701 . https://doi.org/10.1016/j.euf.2016.09.008

Background: Trials in castration-resistant prostate cancer (CRPC) treatment have shown improved outcomes, including survival. However, as trial populations are selected, results may not be representative for the real-world population. The aim of this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a75f4ab2a0be6bc966c310e3b85a39
https://doi.org/10.1016/j.euf.2016.09.008

Zobrazit plný text záznamu

Duodenal perforation following bile duct endoprosthesis placement

Autor: Frank P. J. Peters, Pascal J. H. Kusters, Eric T. P. Keulen

Publikováno v: Endoscopy, 46(S 01), E646-E647. Georg Thieme Verlag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bd179fb2b8ab7b3e236053afc8be64b
https://pubmed.ncbi.nlm.nih.gov/25526406

Zobrazit plný text záznamu

Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)

Autor: I. Skoneczna, Solenn Le-Guennec, Daniel Castellano, Joaquim Bellmunt, Christine Theodore, Frank P. J. Peters, Linda Cerbone, Jean-Pascal Machiels, Cora N. Sternberg, Normand Blais, Marie-Laure Risse, Eric Voog

Publikováno v: Oncology. 85(4)

Background: This open-label, randomized phase III trial evaluated larotaxel/cisplatin versus gemcitabine/cisplatin as first-line treatment for locally advanced (T4b) or metastatic urothelial tract or bladder cancer. Methods: Patients were randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7555e02e01aff14250590b0cb359e118
https://pubmed.ncbi.nlm.nih.gov/24080920

Zobrazit plný text záznamu

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia

Publikováno v: Journal of Clinical Oncology, 31, 4290-6
Journal of clinical oncology, 31(34), 4290-U20. American Society of Clinical Oncology
Journal of Clinical Oncology, 31(34), 4290-U20
Journal of Clinical Oncology, 31(34), 4290-U20. American Society of Clinical Oncology
Journal of Clinical Oncology, 31, 34, pp. 4290-6
Journal of Clinical Oncology, 31(34), 4290-4296. American Society of Clinical Oncology

Purpose Early breast cancer is commonly treated with anthracyclines and taxanes. However, combining these drugs increases the risk of myelotoxicity and may require granulocyte colony-stimulating factor (G-CSF) support. The highest incidence of febril

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cac83957576bcb06458e67615b64369
https://pubmed.ncbi.nlm.nih.gov/23630211

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání